Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Odkrivanje raka materničnega vratu s testiranjem za visokorizične humane viruse papiloma
Avtorji:ID Uršič-Vrščaj, Marjetka (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (110,86 KB)
MD5: 4373774E9B55D2141ED5B78E0FE96282
PID: 20.500.12556/dirros/b28b6054-f369-46f5-bb6b-490ee79c1343
 
Jezik:Slovenski jezik
Tipologija:1.04 - Strokovni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2009
Št. strani:str. 7-10
Številčenje:Letn. 13, št. 1
PID:20.500.12556/DiRROS-8815 Novo okno
UDK:616-006
ISSN pri članku:1408-1741
URN:URN:NBN:SI:doc-O9A4ZXJT
COBISS.SI-ID:25688793 Novo okno
Avtorske pravice:by Authors
Opomba:BSDOCID145197;
Datum objave v DiRROS:31.08.2018
Število ogledov:3532
Število prenosov:856
Metapodatki:XML DC-XML DC-RDF
:
URŠIČ-VRŠČAJ, Marjetka, 2009, Odkrivanje raka materničnega vratu s testiranjem za visokorizične humane viruse papiloma. Onkologija [na spletu]. 2009. Vol. 13, no. 1, p. 7–10. [Dostopano 26 marec 2025]. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=8815
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Onkologija
Skrajšan naslov:Onkologija
Založnik:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:31.08.2018

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Cervical Cancer Detection Using High-Risk Human Papillomavirus Testing
Povzetek:Since the development of cytology-based cervical cancer screening using PAP test in the mid-20th century, the PAP test has been accepted as a method for secondary prevention of cervical cancer. Screening for cervical cancer precursors by cytology has been very successful in the countries with high-quality programs and good coverage of the population at risk. Low-grade abnormalities are the most common type of cytologic abnormalities. In several countries, it is currently recommended to follow up these women by performing PAP smear tests in 6-month intervals. If the low-grade abnormalities do not normalize, colposcopy should be done, which every now and then leads to several unnecessary referrals, associated anxiety and costs. Human papillomavirus (HPV) infection is very common in young women after the onset of sexual activity and, when it persists, it may result in cervical intraepithelial neoplasia (CIN). The recognition of the strong causal relationship between the persistent infection of the genital tract with high-risk HPV types and the occurrence of cervical cancer has resulted in the development of a number of HPV DNA and HPV RNA detection systems. The detection of high-risk HPV DNA is considered to be potentially useful in three applications: (1) as a triage test to select the women with minor cytologic lesions in their PAP smears who need a referral for colposcopic diagnosis and treatment, (2) as a follow-up test for the treated high-grade intraepithelial lesion, and (3.) as a primary screening test alone or in combination with PAP test to detect cervical cancer precursors. There are clear benefits of the use of HPV DNA testing in the triage of atypical squamous cells, mild dyscaryotic cells in older women, and in the post-treatment surveillance of women after treatment for CIN. There is an increasing need for more information and educational programs about HPV.


Arhiv

niGradiv

Nazaj